Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Jan;10(1):143-5.
doi: 10.3201/eid1001.020779.

Antifungal susceptibilities of Cryptococcus neoformans

Lennox K Archibald  1 , Marion J Tuohy, Deborah A Wilson, Okey Nwanyanwu, Peter N Kazembe, Somsit Tansuphasawadikul, Boonchuay Eampokalap, Achara Chaovavanich, L Barth Reller, William R Jarvis, Gerri S Hall, Gary W Procop
Affiliations

Antifungal susceptibilities of Cryptococcus neoformans

Lennox K Archibald et al. Emerg Infect Dis. 2004 Jan.

Abstract

Susceptibility profiles of medically important fungi in less-developed countries remain uncharacterized. We measured the MICs of amphotericin B, 5-flucytosine, fluconazole, itraconazole, and ketoconazole for Cryptococcus neoformans clinical isolates from Thailand, Malawi, and the United States and found no evidence of resistance or MIC profile differences among the countries.

PubMed Disclaimer

References

    1. World Health Organization. Report on infectious diseases 2000: overcoming antimicrobial resistance. WHO/CDC/2000.2. Geneva: The Organization; 2000.
    1. Shears P. Antibiotic resistance in the tropics. Trans R Soc Trop Med Hyg. 2001;95:127–30. 10.1016/S0035-9203(01)90134-8 - DOI - PubMed
    1. Davey KG, Johnson EM, Holmes AD, Szekely A, Warnock DW. In-vitro susceptibility of Cryptococcus neoformans isolates to fluconazole and itraconazole. J Antimicrob Chemother. 1998;42:217–20. 10.1093/jac/42.2.217 - DOI - PubMed
    1. Pfaller M, Zhang J, Messer S, Tumberland M, Mbidde E, Jessup C, et al. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients. Diagn Microbiol Infect Dis. 1998;32:191–9. 10.1016/S0732-8893(98)00095-9 - DOI - PubMed
    1. Pfaller MA, Zhang J, Messer SA, Brandt ME, Hajjeh RA, Jessup CJ, et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob Agents Chemother. 1999;43:169–71. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources